Abstracts tagged "Adalimumab and inflammatory bowel disease (IBD)"

Abstract Number: 1931 • 2012 ACR/ARHP Annual Meeting
Influence of Trough Serum Drug Level and Immunogenicity On the Lack of Response to Adalimumab Therapy in Inflammatory Bowel Disease Patients
Shui Long Wang¹, Scott Hauenstein¹, Linda Ohrmund¹, Reshma Shringarpure², Douglas C. Wolf³, Isam A. Diab⁴, Jared Salbato¹, Rukmini Reddy¹, Kevin McCowen¹, Shawn Shah¹, Steven Lockton¹, Emil Chuang² and Sharat Singh¹, ¹Research and Development, Prometheus Laboratories, San Diego, CA, ²Clinical and Medical Affairs, Prometheus Laboratories, San Diego, CA, ³Atlanta Gastroenterology Associates, Atlanta, GA, ⁴Paramount Medical Research & Consulting, Middleburg Heights, OH
Background/Purpose: Anti-TNF-α therapy is effective for the treatment of inflammatory bowel disease (IBD). Nevertheless, over 30% of IBD patients fail to respond to anti-TNF-α therapy…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Abstracts tagged "Adalimumab and inflammatory bowel disease (IBD)"

Influence of Trough Serum Drug Level and Immunogenicity On the Lack of Response to Adalimumab Therapy in Inflammatory Bowel Disease Patients